MedTrace Logo

The MATCH (Medication Aids for Tobacco Cessation and Health) Study

NCT02146911 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 968

Last updated 2017-02-02

No results posted yet for this study

Summary

Clinically proven medications such as nicotine replacement therapy, bupropion and varenicline are available to help smokers quit but there are not widely used. The primary objective of this study is to evaluate the real-world long-term effectiveness of of bupropion and varenicline treatment in a community sample of smokers interested in quitting. The investigators hypothesize that varenicline treatment will result in higher quit rates at end of treatment and at one year after treatment compared to bupropion. Smoking status will be biochemically confirmed at various time points using salivary cotinine measures. Furthermore, since 50% of the variation in quit success is genetically determined, and the effectiveness of different cessation medication may differ considerably in sub-groups of smokers carrying certain genetic variants, the investigators will collect saliva samples from consenting participants to evaluate the moderating effect of genetics on treatment response.

Conditions

  • Tobacco Use Disorder
  • Nicotine Dependence

Interventions

DRUG

Bupropion

DRUG

Varenicline

BEHAVIORAL

Weekly Motivational Emails

The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.

Sponsors & Collaborators

  • Global Research Awards for Nicotine Dependence (GRAND)

    collaborator UNKNOWN

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Laurie Zawertailo, PhD · Centre for Addiction and Mental Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-01
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146911 on ClinicalTrials.gov